blood urea nitrogen (BUN) 22.7 mg/dL, creatinine 1.06 mg/ dL, and estimated glomerular filtration rate (eGFR) 52.3 mL/ min/1.73 m 2 . We intended to inject mogamulizumab 1.0 mg/ kg, once weekly for 8 weeks. Two days later from the first mogamulizumab administration, plaques and tumors became flattening and dark reddish-brown (Figure 2A-D) . Skin lesions continued to be improved during treatment period ( Figure 2E -H). Modified Severity-Weighted Assessment Tool (mSWAT) score was improved 70 (before the first infusion) to 34 (after the second infusion). As more than 50% of skin lesions were improved, we considered partial response (PR) was achieved. Blood examination revealed normal hematological parameters and liver function during and after the mogamulizumab treatment: hemoglobin 13.5 g/L, WBC 6. Erythema and cracks on his hands, and multiple erythema, papules, and purpuras on his lower legs appeared 19 weeks later from the first mogamulizumab treatment ( Figure 3A-C) . Histopathologically, spongiosis in the epidermis, liquefactive degeneration of basal cells, and lymphocytes, eosinophils, and erythrocytes in the upper dermis was observed ( Figure  3D ). Lymphocytes were CD3 Acute graft-vs-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and cutaneous adverse reactions (CARs) is major adverse events.
Mogamulizumab depletes not only tumor cells but also Foxp3 + regulatory T cells (Tregs) and T cells with Th2 phenotype (Th2-cells) because they also express CCR4 on their surfaces. 9 Depletion of Tregs enhances antitumor immunity, on the other hand, it may cause severe complications such as GVHD. 9 Reduction of Th2-cells results in shifting the Th1/ Th2 balance to the Th1 axis, and it might enhance tissue damage through GVHD. 9 It spends 4 months until the number of Tregs return to baseline level after the last mogamulizumab administration. 10 The rates of acute GVHD are 65.7% for patients who received allo-HSCT within 90 days after the last administration of mogamulizumab, and 28.6% after over 91 days. 9 The shorter interval (<3 months) between the last administration of mogamulizumab and allo-HSCT is highly associated with severe GVHD. 10 In our case, the patient was 77 years old (>70 years old) and had no chance to receive allo-HSCT due to his age even if his illness would have unfortunately become crisis. Therefore, we selected mogamulizumab treatment with not being afraid of the possibility of GVHD. The frequency of all CARs is 34.3%, and the serious one is 10.7%. 6 Rash, erythema, and pruritus are common CARs. 6 Stevens-Johnson syndrome (SJS) and toxic epidermal necrosis (TEN) are reported in 0.8% and 0.6%, respectively. 6 Histological features of CARs are spongiosis in the epidermis, liquefactive degeneration of basal cells, and heavy lymphocyte infiltration in the upper dermis. 11 Infiltrating lymphocytes are positive for CD3, CD8, granzyme B, perforin, and TIA-1. 11 The overall response rate (ORR) and the overall survival (OS) are better in patients with CARs. 8, 11 The ORRs for the patients with and without CARs are 78%-86% and 37%-47%, respectively.
6,11
The OS is significantly longer in patients who experienced CARs (15.7 months) than ones who did not (5.4 months). 8 In our case, PR was achieved, and spongiotic dermatitis with activated cytotoxic T-cells positive for CD8 and granzyme B appeared 10 weeks after from the last administration of mogamulizumab. Furthermore, Foxp3 + Tregs, which had been observed before the mogamulizumab administration, markedly diminished. Depletion of Tregs by mogamulizumab might increase activated cytotoxic T cells and cause CARs. The use of mogamulizumab for patients who have possibility to receive allo-HSCT should be carefully decided owing to the high incidence of GVHD. However, smoldering type ATLL patients with refractory specific skin lesions can be treated with mogamulizumab when they have no plan to receive allo-HSCT due to age or other reasons.
